The global Gastrointestinal Over-the-Counter Drugs Market Comprehensive Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Product (Laxatives, Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal, Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel Anti-Inflammatory, Anti-Emetics), By Indication (Gastroesophageal Reflux Disease (GERD) or Heartburn, Constipation, Diarrhea, Motion Sickness, Flatulence), By End-User (Clinics, Pharmacies, Hospitals, Others)
The Gastrointestinal Over-the-Counter (OTC) Drugs Market involves the production and sale of non-prescription medications used to treat gastrointestinal issues such as indigestion, acid reflux, and constipation. The market is driven by increasing prevalence of gastrointestinal disorders, rising consumer preference for self-medication, and growing availability of OTC drugs. Additionally, advancements in drug formulations and the expansion of retail pharmacy networks support market growth.
The market report analyses the leading companies in the industry including AbbVie Inc, Bausch Health Co. Inc, Bayer AG, Cipla Ltd, Dr Reddys Laboratories Ltd, Eisai Co. Ltd, GlaxoSmithKline Plc, Haleon Plc, Johnson and Johnson Services Inc, Merck KGaA, Novartis AG, Pfizer Inc, Phathom Pharmaceuticals Inc, Prestige Consumer Healthcare Inc, Sanofi SA, and Others.
The most prominent trend in the Gastrointestinal Over-the-Counter Drugs Market is the increased consumer focus on digestive health. With a growing awareness of the importance of gut health for overall wellness, more consumers are turning to OTC gastrointestinal drugs to manage conditions like acid reflux, indigestion, and irritable bowel syndrome. This trend is driven by the rising prevalence of digestive disorders and the desire for convenient, accessible solutions to maintain digestive health​(1)​.
A major driver of the Gastrointestinal Over-the-Counter Drugs Market is the rising incidence of gastrointestinal disorders. Factors such as poor dietary habits, increased stress levels, and sedentary lifestyles are contributing to the growing number of people experiencing digestive issues. As a result, there is a higher demand for effective OTC medications that can provide relief from symptoms and improve quality of life for those affected by these conditions​(1)​.
A significant opportunity in the Gastrointestinal Over-the-Counter Drugs Market lies in the expansion of product lines. Manufacturers can explore the development of new formulations, including natural and herbal options, to cater to the varying preferences of consumers. Additionally, creating targeted products for specific demographics, such as children and the elderly, can help companies capture a broader market share and meet the diverse needs of consumers seeking gastrointestinal relief​(1)​.
The proton pump inhibitors (PPIs) segment is expected to be the fastest-growing in the Gastrointestinal Over-the-Counter (OTC) Drugs Market by product to 2032. PPIs are highly effective in reducing gastric acid production, making them a popular choice for treating conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. The demand for PPIs is driven by the increasing prevalence of gastrointestinal disorders and the rising awareness of the benefits of OTC treatments. Additionally, advancements in drug formulations and the availability of PPIs in various dosage forms contribute to the segment's rapid growth. The expansion of the OTC drugs market and the increasing use of PPIs for self-medication support the growth of this segment.
The gastroesophageal reflux disease (GERD) or heartburn segment is anticipated to be the fastest-growing in the Gastrointestinal Over-the-Counter (OTC) Drugs Market by indication to 2032. The demand for OTC drugs to treat GERD or heartburn is driven by the increasing prevalence of these conditions, which are often associated with modern lifestyles and dietary habits. Consumers are increasingly seeking effective and convenient OTC solutions to manage symptoms of GERD and heartburn. Additionally, advancements in drug formulations and the availability of various OTC options, including antacids, H2 inhibitors, and proton pump inhibitors, contribute to the segment's rapid growth. The expansion of the OTC drugs market and the increasing awareness of the benefits of self-medication support the growth of this segment.
The pharmacies segment is expected to be the fastest-growing in the Gastrointestinal Over-the-Counter (OTC) Drugs Market by end-user to 2032. Pharmacies are a primary point of access for OTC gastrointestinal drugs, offering convenience, professional advice, and a wide range of product options. The demand for OTC drugs in pharmacies is driven by the increasing preference for self-medication and the growing awareness of gastrointestinal health. Additionally, the expansion of retail pharmacy chains and the rising trend of pharmacy-based healthcare services contribute to the segment's rapid growth. The increasing focus on improving access to healthcare and the availability of OTC drugs in various pharmacy channels support the growth of this segment.
By Product
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
By Indication
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Flatulence
By End-User
Clinics
Pharmacies
Hospitals
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
AbbVie Inc
Bausch Health Co. Inc
Bayer AG
Cipla Ltd
Dr Reddys Laboratories Ltd
Eisai Co. Ltd
GlaxoSmithKline Plc
Haleon Plc
Johnson and Johnson Services Inc
Merck KGaA
Novartis AG
Pfizer Inc
Phathom Pharmaceuticals Inc
Prestige Consumer Healthcare Inc
Sanofi SA
*- List Not Exhaustive
Chapter 1. TABLE OF CONTENTS
Chapter 2. Introduction to Gastrointestinal Over The Counter Drugs Market
2.1. Market Overview
2.2. Key Statistics and Report Highlights
2.3. Scope of the Comprehensive Study
2.3.1. Market Definition
2.3.2 Countries and Regions Covered
2.3.3 Research Objective
2.3.4 Units, Currency, and Conversions
2.3.5 Industry Value Chain
2.4. Key Market Segments
2.5. Key Companies
2.6. Study Period
Chapter 3. Strategic Analysis Review
3.1. Gastrointestinal Over The Counter Drugs Pricing Analysis and Forecast
3.2. Porter’s Five Forces
3.3. Market Ecosystem
3.4. SWOT Analysis
3.5. Regulatory Scenario
3.3. Effects of Inflation, Russia-Ukraine War, moderating economic growth, and other macroeconomic factors
Chapter 4. Competitive Landscape
4.1. Market Share Analysis
4.1.1. Global Gastrointestinal Over The Counter Drugs Market Share by Company, 2023
4.1.2. Product Offerings of Leading Gastrointestinal Over The Counter Drugs Companies
4.2. Market Entropy
4.2.1. New Product Launches in the Industry
4.2.2. Mergers, Acquisitions, Joint ventures, and Partnerships
4.3. Key Strategies and Best Practices
Chapter 5. Global Market Projections: Best, Reference, and Low Case Scenarios
5.1. Growth Analysis- Case Scenario Definitions
5.2. Low Growth Case Scenario Forecasts
5.3. Reference Growth Case Scenario Forecasts
5.4. High Growth Case Scenario Forecasts
Chapter 6. Market Dynamics
6.1. Gastrointestinal Over The Counter Drugs Market Drivers
6.2. Gastrointestinal Over The Counter Drugs Market Challenges
6.6. Gastrointestinal Over The Counter Drugs Market Opportunities
6.4. Gastrointestinal Over The Counter Drugs Market Trends
Chapter 7. Global Gastrointestinal Over The Counter Drugs Market Outlook Trends
7.1. Global Gastrointestinal Over The Counter Drugs Revenue (USD Million) and CAGR (%) by Type (2021-2032)
7.2. Global Gastrointestinal Over The Counter Drugs Revenue (USD Million) and CAGR (%) by Application (2021-2032)
7.3. Global Gastrointestinal Over The Counter Drugs Revenue (USD Million) and CAGR (%) by Product (2021-2032)
By Product
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
By Indication
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Flatulence
By End-User
Clinics
Pharmacies
Hospitals
Others
Chapter 8. Global Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.1. Global Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Regions (2021- 2032)
8.2. North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Country (2021-2032)
8.2.1. United States Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.2.2. Canada Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.2.3. Mexico Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.3. Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million), by Country (2021-2032)
8.3.1. Germany Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.3.2. France Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.3.3. United Kingdom Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.3.4. Spain Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.3.5. Italy Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.3.6. Russia Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.3.7. Rest of Europe Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.4. Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Country (2021-2032)
8.4.1. China Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.4.2. Japan Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.4.3. India Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.4.4. South Korea Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.4.5. Australia Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.4.6. South East Asia Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.4.7. Rest of Asia Pacific Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.5. South America Gastrointestinal Over The Counter Drugs Revenue (USD Million), by Country (2021-2032)
8.5.1. Brazil Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.5.2. Argentina Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.5.3. Rest of South America Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.6. Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Country (2021-2032)
8.6.1. Middle East Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
8.6.2. Africa Gastrointestinal Over The Counter Drugs Regional Analysis and Outlook
Chapter 9. North America Gastrointestinal Over The Counter Drugs Analysis and Outlook
9.1. North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Segments (2021-2032)
9.1.1. North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Type (2021-2032)
9.1.2. North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Application (2021-2032)
9.1.3. North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Product (2021-2032)
By Product
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
By Indication
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Flatulence
By End-User
Clinics
Pharmacies
Hospitals
Others
Chapter 10. Europe Gastrointestinal Over The Counter Drugs Analysis and Outlook
10.1. Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million), by Segments (USD Million) (2021-2032)
10.1.1. Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Type (2021-2032)
10.1.2. Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Application (2021-2032)
10.1.3. Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Product (2021-2032)
By Product
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
By Indication
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Flatulence
By End-User
Clinics
Pharmacies
Hospitals
Others
Chapter 11. Asia Pacific Gastrointestinal Over The Counter Drugs Analysis and Outlook
11.1. Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million), and Revenue (USD Million) by Segments (2021-2032)
11.1.1. Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Type (2021-2032)
11.1.2. Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Application (2021-2032)
11.1.3. Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Product (2021-2032)
By Product
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
By Indication
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Flatulence
By End-User
Clinics
Pharmacies
Hospitals
Others
Chapter 12. South America Gastrointestinal Over The Counter Drugs Analysis and Outlook
12.1. South America Gastrointestinal Over The Counter Drugs Revenue (USD Million), by Segments (2021-2032)
12.1.1. South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Type (2021-2032)
12.1.2. South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Application (2021-2032)
12.1.3. South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Product (2021-2032)
By Product
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
By Indication
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Flatulence
By End-User
Clinics
Pharmacies
Hospitals
Others
Chapter 13. Middle East and Africa Gastrointestinal Over The Counter Drugs Analysis and Outlook
13.1. Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million), by Segments (2021-2032)
13.1.1. Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Type (2021-2032)
13.1.2. Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Application (2021-2032)
13.1.3. Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) by Product (2021-2032)
By Product
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
By Indication
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Flatulence
By End-User
Clinics
Pharmacies
Hospitals
Others
Chapter 14. Gastrointestinal Over The Counter Drugs Company Profiles
14.1 Business Overview
14.2 Product Profiles
14.3 SWOT Profiles
14.5 Recent Developments
14.6 Financial Profile
List of Companies
AbbVie Inc
Bausch Health Co. Inc
Bayer AG
Cipla Ltd
Dr Reddys Laboratories Ltd
Eisai Co. Ltd
GlaxoSmithKline Plc
Haleon Plc
Johnson and Johnson Services Inc
Merck KGaA
Novartis AG
Pfizer Inc
Phathom Pharmaceuticals Inc
Prestige Consumer Healthcare Inc
Sanofi SA
15. Methodology and Data Sources
15.1 Customization Offerings
15.2 Subscription Services
15.3 Related Reports
15.4 Publisher Expertise
LIST OF TABLES
Table 1 Market Segmentation Analysis
Table 2 Global Gastrointestinal Over The Counter Drugs Market Share of Leading Companies, 2023
Table 3 Product Offerings of Leading Companies
Table 4 Low Growth Scenario Forecasts
Table 5 Reference Case Growth Scenario
Table 6 High Growth Case Scenario
Table 7 Global Gastrointestinal Over The Counter Drugs Revenue (USD Million) And CAGR (%) By Type (2021-2032)
Table 8 Global Gastrointestinal Over The Counter Drugs Revenue (USD Million) And CAGR (%) By Application (2021-2032)
Table 9 Global Gastrointestinal Over The Counter Drugs Revenue (USD Million) And CAGR (%) By Product (2021-2032)
Table 10 Global Gastrointestinal Over The Counter Drugs Market Revenue (USD Million) By Regions (2021-2032)
Table 11 Global Gastrointestinal Over The Counter Drugs Market Share (%) By Regions (2021-2032)
Table 12 North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Table 13 Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Table 14 Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Table 15 South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Table 16 Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Region (2021-2032)
Table 17 North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Table 18 North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Table 19 North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
Table 20 Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Table 21 Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Table 22 Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
Table 23 Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Table 24 Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Table 25 Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
Table 26 South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Table 27 South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Table 28 South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
Table 29 Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Table 30 Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Table 31 Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
LIST OF FIGURES
Figure 1. Market Scope
Figure 2. Pricing Forecasts Per Unit, 2023- 2032
Figure 3. Porter’s Five Forces
Figure 4. Global Gastrointestinal Over The Counter Drugs Market Revenue (USD Million) By Regions (2021-2032)
Figure 5. Global Gastrointestinal Over The Counter Drugs Market Share (%) By Regions (2023)
Figure 6. North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 7. United States Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 8. Canada Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 9. Mexico Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 10. Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 11. Germany Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 12. France Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 13. United Kingdom Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 14. Spain Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 15. Italy Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 16. Russia Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 17. Rest of Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 11. Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 12. China Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 13. Japan Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 14. India Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 15. South Korea Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 16. Australia Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 17. South East Asia Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 18. South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 19. Brazil Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 20. Argentina Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 21. Rest of Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Country (2021-2032)
Figure 22. Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Region (2021-2032)
Figure 23. Saudi Arabia Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Region (2021-2032)
Figure 24. The UAE Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Region (2021-2032)
Figure 25. Rest of Middle East Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Region (2021-2032)
Figure 26. South Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Region (2021-2032)
Figure 27. Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Region (2021-2032)
Figure 28. North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Figure 29. North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Figure 30. North America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
Figure 31. Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Figure 32. Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Figure 33. Europe Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
Figure 34. Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Figure 35. Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Figure 36. Asia Pacific Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
Figure 37. South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Figure 38. South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Figure 39. South America Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
Figure 40. Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Type (2021-2032)
Figure 41. Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Application (2021-2032)
Figure 42. Middle East and Africa Gastrointestinal Over The Counter Drugs Revenue (USD Million) By Product (2021-2032)
By Product
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
By Indication
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Flatulence
By End-User
Clinics
Pharmacies
Hospitals
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Global Gastrointestinal Over-the-Counter Drugs Market Size is valued at $16.3 Billion in 2024 and is forecast to register a growth rate (CAGR) of 5.4% to reach $24.8 Billion by 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
AbbVie Inc, Bausch Health Co. Inc, Bayer AG, Cipla Ltd, Dr Reddys Laboratories Ltd, Eisai Co. Ltd, GlaxoSmithKline Plc, Haleon Plc, Johnson and Johnson Services Inc, Merck KGaA, Novartis AG, Pfizer Inc, Phathom Pharmaceuticals Inc, Prestige Consumer Healthcare Inc, Sanofi SA
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2032; Currency: Revenue (USD); Volume